J Korean Diabetes > Volume 20(2); 2019 > Article
The Journal of Korean Diabetes 2019;20(2):87-91.
DOI: https://doi.org/10.4093/jkd.2019.20.2.87    Published online July 17, 2019.
Sodium-Glucose Cotransporter 2 억제제의 심혈관 질환 및 신기능악화 예방 효과
Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors.
Jun Hwa Hong
Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea. lammoth@naver.com
Management of hyperglycemia limits progression of microvascular complications in type 2 diabetes mellitus (T2DM). According to large-scale randomized control studies to demonstrate the cardiovascular safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors, SGLT2 inhibitors showed not only cardiovascular safety, but also cardiovascular benefits. Heart failure is adequately prevented by SGLT2 inhibitors regardless of history of heart failure. Additionally, SGLT inhibitors also showed renal protective benefits in slowing the decline of glomerular filtration rate and reducing proteinuria. SGLT2 inhibitors are beneficial to T2DM patients with established cardiovascular disease, high risk of heart failure, and renal impairment. As oral hypoglycemic agents, SGLT2 inhibitors not only control the serum glucose level, but also reduce the macrovascular complications of T2DM.
Key Words: Canagliflozin, Dapagliflozin, Diabetes mellitus, type 2, Empagliflozin

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2023 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer